

Michael B Chancellor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2145991/michael-b-chancellor-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

8,900
citations

57
h-index

86
g-index

272
ext. papers

10,033
ext. citations

2.7
avg, IF

6.14
L-index

#	Paper	IF	Citations
260	Using social media to crowdsource collection of urine samples during a national pandemic.. <i>International Urology and Nephrology</i> , 2022 , 54, 493	2.3	
259	Editorial Comment.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000000244301	2.5	
258	Long COVID and COVID-19-associated cystitis (CAC). <i>International Urology and Nephrology</i> , 2021 , 54, 17	2.3	2
257	Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. <i>European Urology Focus</i> , 2021 , 7, 1448-1467	5.1	1
256	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021 , 11, 7558	4.9	2
255	Improved global response outcome after intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder. <i>International Urology and Nephrology</i> , 2021 , 53, 1331-1338	2.3	1
254	Low Energy Shock Wave Therapy Attenuates Mitochondrial Dysfunction and Improves Bladder Function in HCl induced Cystitis in Rats. <i>Biomedical Journal</i> , 2021 ,	7.1	2
253	Use of Botulinum Toxin in the Genitourinary System. <i>Handbook of Experimental Pharmacology</i> , 2021 , 263, 171-184	3.2	1
252	Voiding defects in acute radiation cystitis driven by urothelial barrier defect through loss of E-cadherin, ZO-1 and Uroplakin III. <i>Scientific Reports</i> , 2021 , 11, 19277	4.9	0
251	Urinary Incontinence and Alzheimer's Disease: Insights From Patients and Preclinical Models.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 777819	5.3	1
250	Proteomic analysis of bladder biopsies from interstitial cystitis/bladder pain syndrome patients with and without Hunner's lesions reveals differences in expression of inflammatory and structural proteins. <i>BMC Urology</i> , 2020 , 20, 180	2.2	1
249	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome-A prospective, multicenter, randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2020 , 39, 1505-1514	2.3	12
248	Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020 , 12, 245-252	1.9	4
247	Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. <i>PLoS ONE</i> , 2020 , 15, e0234682	3.7	179
246	Radiation cystitis modeling: A comparative study of bladder fibrosis radio-sensitivity in C57BL/6, C3H, and BALB/c mice. <i>Physiological Reports</i> , 2020 , 8, e14377	2.6	5
245	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. <i>PLoS ONE</i> , 2020 , 15, e0241388	3.7	3
244	Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. <i>Journal of Clinical Medicine Research</i> , 2020 , 12, 681-682	2.9	13

243	Micturition defects and altered bladder function in the mutant mouse model of aging. <i>American Journal of Clinical and Experimental Urology</i> , 2020 , 8, 81-92	1.6	3
242	Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative. <i>International Neurourology Journal</i> , 2020 , 24, 3-11	2.6	7
241	COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). <i>Medical Hypotheses</i> , 2020 , 145, 110375	3.8	14
240	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine 2020 , 15, e0241388		
239	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine 2020 , 15, e0241388		
238	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine 2020 , 15, e0241388		
237	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine 2020 , 15, e0241388		
236	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
235	Translation, cross-cultural adaptation and validation of the underactive bladder questionnaire to portuguese. <i>International Urology and Nephrology</i> , 2019 , 51, 1329-1334	2.3	1
234	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. <i>International Urology and Nephrology</i> , 2019 , 51, 617-626	2.3	3
233	Radiation Cystitis Modeling: a Comparative Study of Bladder Radiation-Induced Fibrosis in Different Mouse Strains. <i>FASEB Journal</i> , 2019 , 33, 366.1	0.9	
232	Recent Developments in Imaging in BPS/IC. <i>Current Bladder Dysfunction Reports</i> , 2019 , 14, 301-307	0.4	
231	Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse Transcription-Loop-Mediated Isothermal Amplification. <i>Scientific Reports</i> , 2018 , 8, 3803	4.9	40
230	Crowdsourcing Disease Biomarker Discovery Research: The IP4IC Study. <i>Journal of Urology</i> , 2018 , 199, 1344-1350	2.5	4
229	Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 495-505	3.8	8
228	New technology assessment and current and upcoming therapies for underactive bladder. <i>Neurourology and Urodynamics</i> , 2018 , 37, 2932-2937	2.3	7
227	Altered Angiogenic Growth Factors in Urine of Prostate Cancer Survivors With Radiation History and Radiation Cystitis. <i>Urology</i> , 2018 , 120, 180-186	1.6	3
226	Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. <i>BioMed Research International</i> , 2018 , 2018, 7495081	3	6

225	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. <i>Neurourology and Urodynamics</i> , 2018 , 37, 708-715	2.3	7
224	Recent advances in imaging and understanding interstitial cystitis. <i>F1000Research</i> , 2018 , 7,	3.6	15
223	Reverse Transcription-Loop-mediated Isothermal Amplification (RT-LAMP) Assay for Zika Virus and Housekeeping Genes in Urine, Serum, and Mosquito Samples. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	4
222	A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. <i>International Urology and Nephrology</i> , 2018 , 50, 2153-2165	2.3	24
221	Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies. <i>International Urology and Nephrology</i> , 2018 , 50, 1745-1751	2.3	14
220	Patient characteristics for different therapeutic strategies in the management ketamine cystitis. <i>Neurourology and Urodynamics</i> , 2017 , 36, 687-691	2.3	17
219	Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide. <i>Human Gene Therapy</i> , 2017 , 28, 598-609	4.8	9
218	Editorial Comment. <i>Journal of Urology</i> , 2017 , 197, 1495	2.5	
217	Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB). <i>International Urology and Nephrology</i> , 2017 , 49, 777-785	2.3	28
216	OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence. <i>Journal of Urology</i> , 2017 , 197, S224-S225	2.5	3
215	Development of an interstitial cystitis risk score for bladder permeability. <i>PLoS ONE</i> , 2017 , 12, e0185686	3.7	11
214	Advantage of urine based molecular diagnosis of Zika virus. <i>International Urology and Nephrology</i> , 2016 , 48, 1961-1966	2.3	15
213	A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. <i>International Urology and Nephrology</i> , 2016 , 48, 1797-1802	2.3	15
212	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F548-54	4.3	10
211	Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats. <i>International Urology and Nephrology</i> , 2016 , 48, 1407-12	2.3	3
210	Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. <i>Life Sciences</i> , 2016 , 167, 98-104	6.8	10
209	Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. <i>International Urology and Nephrology</i> , 2016 , 48, 1029-36	2.3	32
208	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016 , 91, 21-32	1.6	11

207	Modeling and Treatment of Radiation Cystitis. <i>Urology</i> , 2016 , 88, 14-21	1.6	29
206	Spinal glycine transporter-1 inhibition influences the micturition reflex in urethane-anesthetized rats. <i>International Urology and Nephrology</i> , 2016 , 48, 349-54	2.3	
205	Liposome Based Intravesical Therapy Targeting Nerve Growth Factor Ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. <i>Journal of Urology</i> , 2016 , 195, 1920-6	2.5	18
204	Botulinum Toxin to Treat Neurogenic Bladder. <i>Seminars in Neurology</i> , 2016 , 36, 5-9	3.2	9
203	Urodynamics Evaluation of Underactive Bladder 2016 , 25-50		0
202	Pathophysiology and Animal Modeling of Underactive Bladder 2016 , 51-68		1
201	Role of the Anterior Cingulate Cortex in the Control of Micturition Reflex in a Rat Model of Parkinson's Disease. <i>Journal of Urology</i> , 2016 , 195, 1613-1620	2.5	16
200	Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis. <i>Reviews in Urology</i> , 2016 , 18, 57-65	1	14
199	Current Drug Therapy for Underactive Bladder 2016 , 83-93		1
198	Surgery for Underactive Bladder Treatment 2016 , 135-154		
197	Epidemiology and Demographics of Underactive Bladder 2016 , 1-11		0
196	Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 406-13	1.9	17
195	Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. <i>Toxins</i> , 2016 , 8,	4.9	18
194	Age-related changes in bladder function with altered angiotensin II receptor mechanisms in rats. <i>Neurourology and Urodynamics</i> , 2016 , 35, 908-913	2.3	3
193	Modeling of chronic radiation-induced cystitis in mice. <i>Advances in Radiation Oncology</i> , 2016 , 1, 333-343	3.3	18
192	Reply to the letter: Urine based molecular diagnosis of Zika virus by Viroj Wiwanitkit. <i>International Urology and Nephrology</i> , 2016 , 48, 2025	2.3	1
191	Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2016 , 35, 595-600	2.3	5
190	Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study. <i>International Urology and Nephrology</i> , 2015 , 47, 465-7	2.3	32

189	Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder. <i>Journal of Urology</i> , 2015 , 194, 1329-35	2.5	1
188	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. <i>Urology</i> , 2015 , 85, 1284-90	1.6	7
187	Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. <i>Journal of Urology</i> , 2015 , 194, 578-84	2.5	23
186	Use of botulinum toxin for genitourinary conditions: What is the evidence?. <i>Toxicon</i> , 2015 , 107, 141-7	2.8	7
185	Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis. <i>International Urology and Nephrology</i> , 2015 , 47, 1679-81	2.3	14
184	Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 555-70	3.7	21
183	Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. <i>Neurourology and Urodynamics</i> , 2015 , 34, 79-84	2.3	49
182	Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015 , 7, 77-83	1.9	10
181	Bladder uptake of liposomes after intravesical administration occurs by endocytosis. <i>PLoS ONE</i> , 2015 , 10, e0122766	3.7	23
180	Effects of Duloxetine on Urethral Continence Reflex and Bladder Activity in Rats with Cerebral Infarction. <i>Journal of Urology</i> , 2015 , 194, 842-7	2.5	9
179	Underactive Bladder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015 , 31, 523-33	3.8	15
178	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0134803	3.7	8
177	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. <i>Reviews in Urology</i> , 2015 , 17, 179-89	1	
176	Intravesical liposome drug delivery and IC/BPS. <i>Translational Andrology and Urology</i> , 2015 , 4, 572-8	2.3	5
175	Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. <i>Journal of Urology</i> , 2014 , 192, 1743-9	2.5	65
174	Autologous muscle derived cells for treatment of stress urinary incontinence in women. <i>Journal of Urology</i> , 2014 , 192, 469-76	2.5	83
173	Optimum Management of Overactive Bladder: Medication vs Botox □ vs InterStim □ vs Urgent □ PC. <i>Urology Practice</i> , 2014 , 1, 7-12	0.8	5
172	Functional and molecular characterization of hyposensitive underactive bladder tissue and urine in streptozotocin-induced diabetic rat. <i>PLoS ONE</i> , 2014 , 9, e102644	3.7	24

171	Epidemiology and demographics of the underactive bladder: a cross-sectional survey. <i>International Urology and Nephrology</i> , 2014 , 46 Suppl 1, S7-10	2.3	34
170	Defining and advancing education and conservative therapies of underactive bladder. <i>International Urology and Nephrology</i> , 2014 , 46 Suppl 1, S29-34	2.3	4
169	Advanced therapeutic directions to treat the underactive bladder. <i>International Urology and Nephrology</i> , 2014 , 46 Suppl 1, S35-44	2.3	12
168	Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome. <i>ISRN Pharmacology</i> , 2014 , 2014, 601653		8
167	Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. <i>International Urology and Nephrology</i> , 2014 , 46, 2291-5	2.3	27
166	Statin-Associated Underactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014 , 6, 124-5	1.9	1
165	Advances in Therapeutic Development for Radiation Cystitis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014 , 6, 1-10	1.9	12
164	The overactive bladder progression to underactive bladder hypothesis. <i>International Urology and Nephrology</i> , 2014 , 46 Suppl 1, S23-7	2.3	53
163	Pathophysiology and animal modeling of underactive bladder. <i>International Urology and Nephrology</i> , 2014 , 46 Suppl 1, S11-21	2.3	44
162	Neural mechanisms underlying lower urinary tract dysfunction. <i>Korean Journal of Urology</i> , 2014 , 55, 81-90		19
161	Pilot study of liposome-encapsulated onabotulinumtoxin A for patients with overactive bladder: a single-center study. <i>European Urology</i> , 2014 , 65, 1117-24	10.2	78
160	Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014 , 46, 871-7	2.3	33
159	Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 174-179	0.4	1
158	Intravesical drug delivery for dysfunctional bladder. <i>International Journal of Urology</i> , 2013 , 20, 552-62	2.3	32
157	Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. <i>Journal of Urology</i> , 2013 , 189, 595-601	2.5	94
156	Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. <i>Clinical Therapeutics</i> , 2013 , 35, 1744-51	3.5	78
155	Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. <i>Journal of Urology</i> , 2013 , 190, 757-64	2.5	35
154	Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. <i>Journal of Urology</i> , 2013 , 189, 1553-8	2.5	18

153	Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. <i>Toxicon</i> , 2013 , 67, 129-40	2.8	24
152	Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. <i>European Urology</i> , 2013 , 64, 610-21	10.2	41
151	OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. <i>Neurology</i> , 2013 , 81, 841-8	6.5	37
150	OnabotulinumtoxinA Has No Effects on Growth of LNCaP and PC3 Human Prostate Cancer Cells. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013 , 5, 168-72	1.9	4
149	The other bladder syndrome: underactive bladder. <i>Reviews in Urology</i> , 2013 , 15, 11-22	1	91
148	Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients. <i>International Journal of MS Care</i> , 2013 , 15, 182-92	2.3	30
147	Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. <i>BJU International</i> , 2012 , 110, 401-7	5.6	26
146	Anticholinergics for overactive bladder therapy: central nervous system effects. <i>CNS Neuroscience and Therapeutics</i> , 2012 , 18, 167-74	6.8	70
145	Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. <i>Journal of Urology</i> , 2012 , 187, 2243-8	2.5	64
144	Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. <i>Drugs and Aging</i> , 2012 , 29, 259-73	4.7	61
143	Physiology and Pharmacology of the Bladder and Urethra 2012 , 1786-1833.e17		12
142	Mirabegron: a safety review. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 287-94	4.1	37
141	Botulinum Toxin in Urology 2011 ,		4
140	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011 , 3, 2-9	1.9	8
139	Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. <i>BJU International</i> , 2011 , 108, 248-51	5.6	46
138	Development of cellular therapy for the treatment of stress urinary incontinence. <i>International Urogynecology Journal</i> , 2011 , 22, 1075-83	2	32
137	Neurotoxin Use for Voiding Dysfunction. <i>Current Bladder Dysfunction Reports</i> , 2011 , 6, 182-189	0.4	
136	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. <i>Neurourology and Urodynamics</i> , 2011 , 30, 421-7	2.3	29

135	Botulinum Toxin Injection for Prostate Disorders 2011 , 111-130		
134	Overactive Bladder and Idiopathic Detrusor Overactivity 2011 , 61-78		
133	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. <i>BJU International</i> , 2010 , 106, 1681-5	5.6	81
132	Botulinum toxin for the lower urinary tract. <i>BJU International</i> , 2010 , 105, 1046-58	5.6	21
131	Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. <i>Journal of Urology</i> , 2010 , 184, 2416-22	2.5	286
130	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2010 , 2, 88-94	1.9	26
129	Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. <i>Neurourology and Urodynamics</i> , 2010 , 29, 551-4	2.3	13
128	Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. <i>International Urology and Nephrology</i> , 2010 , 42, 383-91	2.3	19
127	Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. <i>International Urology and Nephrology</i> , 2010 , 42, 629-35	2.3	109
126	Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. <i>European Urology</i> , 2010 , 58, 532-43	10.2	75
125	State of the art in intravesical therapy for lower urinary tract symptoms. <i>Reviews in Urology</i> , 2010 , 12, e181-9	1	11
124	PP-436 ??????????galanin???(?????,?98????????????). <i>Japanese Journal of Urology</i> , 2010 , 101, 477		
123	Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. <i>European Urology</i> , 2009 , 56, 700-6	10.2	138
122	Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. <i>European Urology</i> , 2009 , 56, 159-66	10.2	70
121	Transabdominal Ultrasound Measurement of Detrusor Wall Thickness in Patients with Overactive Bladder. <i>Tzu Chi Medical Journal</i> , 2009 , 21, 129-135	1.1	7
120	Cystometric Changes in Pressure-guided Acute Distension Rat Model of the Underactive Bladder□ <i>Tzu Chi Medical Journal</i> , 2009 , 21, 136-139	1.1	2
119	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. <i>BJU International</i> , 2009 , 103, 1668-72	5.6	82
118	Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. <i>BJU International</i> , 2009 , 104, 657-61	5.6	131

117	Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. <i>BJU International</i> , 2009 , 104, 1158-62	5.6	21
116	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. <i>BJU International</i> , 2009 , 104, 1476-81	5.6	99
115	Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. <i>Urology</i> , 2009 , 73, 421-6	1.6	59
114	Diabetes-induced alternations in biomechanical properties of urinary bladder wall in rats. <i>Urology</i> , 2009 , 73, 911-5	1.6	34
113	Bladder Botulinum Toxin. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S22-S25	1.9	1
112	Role of Sarco/Endoplasmic Reticulum Calcium ATPase in Lower Urinary Tract Smooth Muscles. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S50-S52	1.9	2
111	Novel Biomarkers for Diagnosis and Therapeutic Assessment of Overactive Bladder: Urinary Nerve Growth Factor and Detrusor Wall Thickness. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S59-S61	1.9	
110	Muscle-derived Stem Cell Therapy for Stress Urinary Incontinence. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S62-S65	1.9	
109	Noninvasive Videourodynamics Using Transperineal Doppler Ultrasonography. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S80-S83	1.9	
108	Lower Urinary Tract: Diabetes Mellitus-focused on Recent Experimental Results. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S87-S89	1.9	1
107	Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S90-S93	1.9	2
106	Biomechanics of Diabetic Bladders. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S94-S97	1.9	
105	Gene Therapy for Neurogenic Erectile Dysfunction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009 , 1, S44-S47.	1.9	
104	Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. <i>Journal of Urology</i> , 2009 , 182, 786-92	2.5	92
103	Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009 , 35, 76-83	2	56
102	OP-051 ???(Neurourology/??1,?????,?97????????????). <i>Japanese Journal of Urology</i> , 2009 , 100, 201		
101	IL4 Botulinum Toxin for LUTS Past, Present and Future(The 97th Annual Meeting of the Japanese Urological Association). <i>Japanese Journal of Urology</i> , 2009 , 100, 43		
100	Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. <i>BJU International</i> , 2008 , 102, 704-6	5.6	38

99	Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. <i>BJU International</i> , 2008 , 102, 1440-4	5.6	52
98	Neurotoxin Versus Neuromodulation for the Treatment of Refractory Overactive Bladder Syndrome. <i>Tzu Chi Medical Journal</i> , 2008 , 20, 109-111	1.1	1
97	Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. <i>Journal of Urology</i> , 2008 , 180, 742-8	2.5	72
96	Proteomic investigation on chronic bladder irritation in the rat. <i>Urology</i> , 2008 , 71, 536-40	1.6	6
95	Time-dependent alterations of select genes in streptozotocin-induced diabetic rat bladder. <i>Urology</i> , 2008 , 71, 1214-9	1.6	17
94	Case for pharmacotherapy development for underactive bladder. <i>Urology</i> , 2008 , 72, 966-7	1.6	38
93	Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. <i>Clinical Therapeutics</i> , 2008 , 30, 1766-81	3.5	43
92	A PILOT STUDY OF AAV1/SERCA2a GENE TRANSFER IN THE RAT STRESS URINARY INCONTINENCE MODEL. <i>Journal of Urology</i> , 2008 , 179, 534-535	2.5	2
91	Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008 , 294, R1510-6	3.2	17
90	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. <i>Nature Reviews Urology</i> , 2008 , 5, 319-28		93
89	Physiological effects of human muscle-derived stem cell implantation on urethral smooth muscle function. <i>International Urogynecology Journal</i> , 2008 , 19, 1229-34	2	15
88	Diagnosis of incontinence. <i>Reviews in Urology</i> , 2008 , 10, 242-3	1	
87	Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder?. <i>Reviews in Urology</i> , 2008 , 10, 306-8	1	3
86	Human muscle-derived cell injection in a rat model of stress urinary incontinence. <i>Muscle and Nerve</i> , 2007 , 36, 391-3	3.4	21
85	Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. <i>European Urology</i> , 2007 , 51, 1119-27	10.2	62
84	The promise of stem cell therapy to restore urethral sphincter function. <i>Current Urology Reports</i> , 2007 , 8, 373-8	2.9	12
83	Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F639-46	4.3	47
82	Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. <i>Geriatrics</i> , 2007 , 62, 15-24		11

81	Botulinum: A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. <i>Current Prostate Reports</i> , 2006 , 4, 75-80		
80	Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. <i>Journal of Urology</i> , 2006 , 176, 1673-8	2.5	88
79	The application of botulinum toxin in the prostate. <i>Journal of Urology</i> , 2006 , 176, 2375-82	2.5	72
78	Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. <i>Journal of Urology</i> , 2006 , 175, 1158-63	2.5	120
77	Functional analysis of active urethral closure mechanisms under sneeze induced stress condition in a rat model of birth trauma. <i>Journal of Urology</i> , 2006 , 176, 2711-5	2.5	45
76	The overactive bladder: Epidemiology and morbidity. <i>Urologic Clinics of North America</i> , 2006 , 33, 433-8, vii	2.9	30
75	Periurethral cellular injection: comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. <i>Urology</i> , 2006 , 68, 449-54	1.6	101
74	Pharmacotherapy for neurogenic detrusor overactivity. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2006 , 85, 536-45	2.6	74
73	Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. <i>BJU International</i> , 2006 , 98, 1033-7; discussion 1337	5.6	90
72	Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. <i>Urology</i> , 2005 , 65, 37-41	1.6	147
71	Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. <i>Urology</i> , 2005 , 66, 775-9	1.6	100
70	Detrusor overactivity induced by intravesical application of adenosine 5Rtriphosphate under different delivery conditions in rats. <i>Urology</i> , 2005 , 66, 1332-7	1.6	50
69	alpha1-Adrenergic mechanism in diabetic urethral dysfunction in rats. <i>Journal of Urology</i> , 2005 , 173, 1027-32	5.2	32
68	Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. <i>BJU International</i> , 2005 , 95, 733-8	5.6	133
67	Pittsburgh experience with lower urinary tract botulinum toxin A injection. <i>Current Urology Reports</i> , 2005 , 6, 235-6	2.9	
66	Recent advances in the neurophysiology of stress urinary incontinence. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 39, 21-4		40
65	Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. <i>Journal of Endourology</i> , 2005 , 19, 880-2	2.7	48
64	Treatment of stress urinary incontinence with duloxetine hydrochloride. <i>Reviews in Urology</i> , 2005 , 7, 81-6	1	13

63	Tissue Engineering to Rebuild the Lower Urinary Tract. <i>Japanese Journal of Urology</i> , 2005 , 96, 54-55		
62	Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. <i>Diabetes</i> , 2004 , 53, 2723-30	0.9	80
61	Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. <i>Journal of Urology</i> , 2004 , 171, 483-9	2.5	51
60	Urethral dysfunction in diabetic rats. <i>Journal of Urology</i> , 2004 , 171, 1959-64	2.5	72
59	Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. <i>Journal of Urology</i> , 2004 , 172, 1529-32	2.5	211
58	Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. <i>Journal of Urology</i> , 2004 , 171, 478-82	2.5	93
57	Emerging role of botulinum toxin in the management of voiding dysfunction. <i>Journal of Urology</i> , 2004 , 171, 2128-37	2.5	154
56	Treatment of interstitial cystitis. <i>Urology</i> , 2004 , 63, 85-92	1.6	95
55	Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. <i>Urology</i> , 2004 , 63, 780-5	1.6	89
54	Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. <i>Urology</i> , 2004 , 64, 871-5; discussion 875	1.6	213
53	The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2004 , 287, F434-41	4.3	78
52	Implications of diabetes mellitus in urology. <i>Urologic Clinics of North America</i> , 2003 , 30, 1-12	2.9	70
51	Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. <i>Journal of Urology</i> , 2003 , 169, 1896-900	2.5	146
50	Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. <i>Urology</i> , 2003 , 62, 958-63	1.6	135
49	Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. <i>Brain Research Bulletin</i> , 2003 , 61, 165-71	3.9	54
48	Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003 , 285, R356-65	3.2	94
47	New Frontiers in the Treatment of Overactive Bladder. <i>Journal of the Korean Continence Society</i> , 2003 , 7, 1		
46	Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord Reduces Bladder Hyperreflexia in Spinal Cord Injured Rats.. <i>Journal of Urology</i> , 2002 , 168, 2269-2274	2.5	156

45	Effect of cryoinjury on the contractile parameters of bladder strips: a model of impaired detrusor contractility. <i>Brain Research Bulletin</i> , 2002 , 59, 23-8	3.9	29
44	Diabetic Cystopathy Correlates With a Long-Term Decrease in Nerve Growth Factor Levels in The Bladder and Lumbosacral Dorsal Root Ganglia. <i>Journal of Urology</i> , 2002 , 168, 1259-1264	2.5	99
43	Passive Biaxial Mechanical Properties of the Rat Bladder Wall After Spinal Cord Injury. <i>Journal of Urology</i> , 2002 , 167, 2247-2252	2.5	56
42	Botulinum Toxin Urethral Sphincter Injection to Restore Bladder Emptying in a Woman With Multiple Sclerosis. <i>International Journal of MS Care</i> , 2002 , 4, 70-72	2.3	3
41	Urologic Applications of Botulium Toxin. <i>Journal of the Korean Continence Society</i> , 2002 , 6, 22		
40	Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. <i>Journal of Urology</i> , 2002 , 168, 1259-64	2.5	40
39	Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. <i>Neurourology and Urodynamics</i> , 2001 , 20, 61-71	2.3	35
38	Genitourinary tract patent update. <i>Expert Opinion on Therapeutic Patents</i> , 2001 , 11, 17-31	6.8	5
37	Autologous primary muscle-derived cells transfer into the lower urinary tract. <i>Tissue Engineering</i> , 2001 , 7, 395-404		49
36	THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTOR. <i>Journal of Urology</i> , 2001 , 165, 975-979	2.5	122
35	BOTULINUM TOXIN URETHRAL SPHINCTER INJECTION TO RESTORE BLADDER EMPTYING IN MEN AND WOMEN WITH VOIDING DYSFUNCTION. <i>Journal of Urology</i> , 2001 , 165, 1107-1110	2.5	169
34	Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. <i>Journal of Urology</i> , 2001 , 165, 271-6	2.5	92
33	HERPES SIMPLEX VIRUS MEDIATED NERVE GROWTH FACTOR EXPRESSION IN BLADDER AND AFFERENT NEURONS: POTENTIAL TREATMENT FOR DIABETIC BLADDER DYSFUNCTION. <i>Journal of Urology</i> , 2001 , 165, 1748-1754	2.5	76
32	Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. <i>Neurourology and Urodynamics</i> , 2000 , 19, 279-87	2.3	147
31	Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions. <i>Neuromodulation</i> , 2000 , 3, 16-26	3.1	73
30	Myoblast therapy for stress urinary incontinence and bladder dysfunction. <i>World Journal of Urology</i> , 2000 , 18, 56-61	4	54
29	Discussion: resiniferatoxin-preliminary data. <i>BJU International</i> , 2000 , 55, 65; discussion 66	5.6	1
28	LONG-TERM RESULTS OF SACRAL NERVE STIMULATION (S3) FOR THE TREATMENT OF NEUROGENIC REFRACTORY URGE INCONTINENCE RELATED TO DETRUSOR HYPERREFLEXIA. <i>Journal of Urology</i> , 2000 , 164, 1476-1480	2.5	124

27	Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. <i>Journal of Urology</i> , 1999 , 162, 2211-6	2.5	112
26	Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. <i>Journal of Urology</i> , 1999 , 162, 204-12	2.5	193
25	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART I: EXPERIMENTAL URETHRA. <i>Journal of Urology</i> , 1998 , 160, 1787-1791	2.5	20
24	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART II: CLINICAL APPLICATION IN BLADDER OUTLET OBSTRUCTION. <i>Journal of Urology</i> , 1998 , 160, 1792-1796	2.5	31
23	In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats. <i>Journal of Spinal Cord Medicine</i> , 1997 , 20, 31-5	1.9	3
22	Should we be using chili pepper extracts to treat the overactive bladder?. <i>Journal of Urology</i> , 1997 , 158, 2097	2.5	7
21	Gracilis urethromyoplasty--an autologous urinary sphincter for neurologically impaired patients with stress incontinence. <i>Spinal Cord</i> , 1997 , 35, 546-9	2.7	6
20	Gracilis muscle transposition with electrical stimulation for sphincteric incontinence: a new approach. <i>World Journal of Urology</i> , 1997 , 15, 320-8	4	7
19	Uroflowmetry37-45		
18	Normal Micturition11-21		1
17	Stress Incontinence in Women184-196		1
16	Rapid Detection of Novel Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification		48
15	Cerebral Vascular Accident, Parkinson's Disease and Other Supra Spinal Neurologic Disorders152-165		8
14	Leak Point Pressure46-55		1
13	Pre-Urodynamic Evaluation1-10		
12	Benign Prostatic Hyperplasia, Bladder Neck Obstruction, and Prostatitis96-119		
11	Bladder Outlet Obstruction and Impaired Detrusor Contractility in Women120-144		
10	Neurogenic Bladder: The Effect of Neurologic Lesions on Micturition145-151		

- 9 Spinal Cord Injury, Multiple Sclerosis, and Diabetes Mellitus166-183
- 8 Genital Prolapse197-211
- 7 Sphincteric Incontinence in Men and Other Complications of Prostate Cancer Treatment212-226
- 6 Enterocystoplasty and Neobladder227-234
- 5 Cystometry22-36
- 4 Low Bladder Compliance56-61
- 3 Videourodynamics62-68
- 2 Pitfalls in Interpretation of Urodynamic Studies69-82
- 1 Overactive Bladder83-95